Dr. Brian J. Moran, Awareness in Action and Sky High Referral Rates
Dr. Brian J. Moran is the Medical Director for the Chicago Prostate Cancer Center. The Chicago Prostate Cancer Center is a specialty center that practices low-dose rate brachytherapy and has performed over 20,000 low-dose rate prostate implants since they were founded in 1997.
“Today, over 85% of our [low-dose rate brachytherapy] patients are referred from former, satisfied patients,” says Moran. Because of this, Dr. Moran recognizes the value of brachytherapy in the community and the awareness in action. Former patients have even a monthly support group meeting that Dr. Moran and his Director of Research and Education attend.
Dr. Moran credits the baby boomer generation with this awareness in action. Whether it’s through social media or simply talking to a friend, patients are being introduced to brachytherapy through channels that weren’t available 10 years ago. Dr. Moran hopes to use these new channels to share patients’ stories and testimonials.
The more widely those stories are shared, the greater the opportunity for more men to take an active role in their treatment and reaching optimal quality of life thereafter.
That said, Dr. Moran notes that the internet is not always a reliable source and that he hopes to always provide patients with the most accurate and valuable information when making their treatment decision.
If you would like to learn more about how brachytherapy improves outcomes for many types of cancer patients, especially prostate cancer patients, contact email@example.com.
Advantageous biological effect, Cesium-131’s short half-life, and new shielded or dynamically modulated sources: Dr. Mark Rivard’s thoughts on brachytherapy from ABS 2018
As a physicist, Dr. Mark Rivard is fascinated by brachytherapy’s ability to provide “conformal, localized” radiotherapy compared to external-beam radiation therapy for treatment of multiple cancer types.
RICHLAND, WASHINGTON – December 3, 2018 – IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, announced that Jonathan Hunt has been named Chief Financial Officer...
ASTRO 2018 Insights: building community, innovating and celebrating strong data around the power of Cesium
Building community around the power of Cesium The radiation oncologist community is one of the cornerstones on which we are building the future of brachytherapy at Isoray. As such, in person engagements at the ASTRO Annual Meeting are some of our most important...